Yi-ping Lu

Dr. Yi-ping Lu

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SLShengzhuo Liu
Shengzhuo Liu
JLJiayu Liang
Jiayu Liang
ZLZhihong Liu
Zhihong Liu
CZChi Zhang
Chi Zhang
YWYang Wang
Yang Wang
XWXianding Wang
Xianding Wang
Objective: Aberrant expression of the immune checkpoint molecule, CD276, also known as B7-H3, is associated with tumorigenesis. In this review, we aim to comprehensively describe the role of CD276 in malignancies and its potential therapeutic effect. Data Sources: Database including PubMed, EMbase, Cochrane Library, CNKI, and Clinical Trails.gov were searched for eligible studies and reviews. Study selection: Original studies and review articles on the topic of CD276 in tumors were retrieved. Results: CD276 is an immune checkpoint molecule in the epithelial mesenchymal transition (EMT) pathway. In this review, we evaluated the available evidence on the expression and regulation of CD276. We also assessed the role of CD276 within the immune micro-environment, effect on tumor progression, and the potential therapeutic effect of CD276 targeted therapy for malignancies. Conclusion: CD276 plays an essential role in cell proliferation, invasion, and migration in malignancies. Results from most recent studies indicate CD276 could be a promising therapeutic target for malignant tumors.

4 June 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Yongquan TangYongquan Tang
Yongquan Tang
ZLZhihong Liu
Zhihong Liu
ZZZijun Zou
Zijun Zou
JLJiayu Liang
Jiayu Liang
YLYi-ping Lu
Yi-ping Lu
YZYuchun Zhu
Yuchun Zhu
Background. The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy. We aimed to assess the prognostic benefits of adjuvant mitotane after resection of ACC in patients without distant metastasis.Methods. The PubMed, WoS, Embase, and Cochrane Library databases were systematically searched. Recurrence-free survival (RFS) and overall survival (OS) were adopted as measurements. A meta-analysis was conducted based on hazard ratio (HR) with 95% confidence interval (CI). A study was included only if the enrolled patients underwent resection of ACC without adjuvant chemotherapy except mitotane.Results. A total of 5 retrospective studies reporting on 1249 patients were included for this meta-analysis. The meta-analysis showed that adjuvant mitotane was significantly associated with prolonged RFS (HR = 0.62; 95%CI, 0.42-0.94; P < 0.05) and prolonged OS (HR = 0.69; 95%CI, 0.55-0.88, P < 0.05).Conclusion. After comprehensive review, current evidence suggests that adjuvant mitotane significantly decreases the recurrence rate and mortality after resection of ACC in patients without distant metastasis, but these findings need further demonstration from prospective controlled trials.

30 August 2016 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
ZZZi-Jun Zou
Zi-Jun Zou
ZLZhi-Hong Liu
Zhi-Hong Liu
LTLiang-You Tang
Liang-You Tang
YWYu-Jie Wang
Yu-Jie Wang
JLJia-Yu Liang
Jia-Yu Liang
YLYi-ping Lu
Yi-ping Lu

1 December 2018 in Surgery
Verified
Journal Article
Closed access
KWKan Wu
Kan Wu
ZLZhihong Liu
Zhihong Liu
JLJiayu Liang
Jiayu Liang
YTYongquan Tang
Yongquan Tang
ZZZijun Zou
Zijun Zou
YLYi-ping Lu
Yi-ping Lu

1 August 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JLJiayu Liang
Jiayu Liang
XWXin Wei
Xin Wei
ZLZhihong Liu
Zhihong Liu
DCDehong Cao
Dehong Cao
YTYongquan Tang
Yongquan Tang
YLYi-ping Lu
Yi-ping Lu

26 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJiayu Liang
Jiayu Liang
ZLZhihong Liu
Zhihong Liu
ZZZijun Zou
Zijun Zou
YTYongquan Tang
Yongquan Tang
CZChuan Zhou
Chuan Zhou
YLYi-ping Lu
Yi-ping Lu
Both epithelial-mesenchymal transition (EMT) and immune regulation are important biological process in malignant tumours. The current research aims to comprehensively explore the potential association between the epithelial-mesenchymal transition (EMT) signature and immune checkpoint signature and its role in predicting the prognosis of clear-cell renal cell carcinoma (ccRCC) patients. EMT-related genes were collected from an experiment-based study and then were investigated using data from the Cancer Genome Atlas. A total of 357 genes were included, and 23 of them that were upregulated and correlated with prognosis were analysed further as core EMT genes in ccRCC. Interestingly, the emerging immune checkpoints CD276, OX40 and TGFB1 were found to be significantly co-expressed with core EMT genes, and TGFB1, CXCR4, IL10, and IL6 were the most important molecules potentially interacting with EMT molecules in our model, as determined from mRNA co-expression and protein-protein interaction network analysis. Additionally, an integrated scoring model based on FOXM1, TIMP1 and IL6 was successfully established to distinguish ccRCC patients with different clinical risks. Our results identified core genes in the EMT-immunophenotyping correlation and evaluated their risk assessment capabilities, providing more potential therapeutic targets and prediction approaches regarding the translational research of treatment and prognosis in ccRCC.